Comparative Pharmacology
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus CIPROFLOXACIN IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO IN DEXTROSE 5 IN PLASTIC CONTAINER versus CIPROFLOXACIN IN DEXTROSE 5.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER vs CIPROFLOXACIN IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
400 mg intravenously every 8-12 hours over 60 minutes.
400 mg IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 4 hours (range 3-7 hours) in patients with normal renal function; extends to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 3.5-5 hours in healthy adults, prolonged to 6-10 hours in elderly or mild renal impairment, and up to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 50% of elimination, with 15% as metabolites; biliary/fecal excretion contributes about 20-35%.
Renal excretion accounts for approximately 50-70% of an administered dose as unchanged drug; biliary/fecal excretion accounts for about 20-35% (including active drug and metabolites).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic